Where does Indigo Diabetes N.V. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Indigo Diabetes N.V. ranks #32,039 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Indigo Diabetes N.V. hold?

Indigo Diabetes N.V. holds 8 US utility patents granted between 2018 and 2024, spanning 9 technology areas.

What is Indigo Diabetes N.V.'s Innovation Score?

Indigo Diabetes N.V. has an Innovation Score of 47.9 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Indigo Diabetes N.V. focus on?

Indigo Diabetes N.V.'s top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 5 patents, ranking #3,118 of 7,127 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Indigo Diabetes N.V.'s patent grant rate increasing or decreasing?

Indigo Diabetes N.V.'s recent grant velocity is +600% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Indigo Diabetes N.V.'s patents?

Indigo Diabetes N.V.'s patents average 16.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Indigo Diabetes N.V. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Indigo Diabetes N.V.

USPTO PatentsView assignee record - 8 granted patents across 9 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Indigo ranks #32,039 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 9 technology areas.

#32,039
of 49,997 US assignees by volume: Top 18%
by Innovation Score (47.9/100): 16.1
avg claims per patent: +600%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32039 · Foreign Corporation #32,039 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,039/49,997
PHOTO-FINISH Incodema3D
CPC-NARROW A61B · 9 areas
INNOV-PAR 47.9/100
CLAIMS-RICH 16.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +600% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Incodema3D, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Indigo’s 47.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (16%) Velocity 20.0 pts (42%) Breadth 10.6 pts (22%) Claim depth 9.7 pts (20%)

Qualcomm Incorporated · highest

85
Indigo Diabetes · this assignee

48
3D Lighting… · lowest

7

What this shows Indigo's Innovation Score is 47.9/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Indigo?

Each dot is one of Indigo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Indigo’s own 16.1 claims/patent is at or below the 18.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Indigo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Indigo's grants concentrate

Indigo Diabetes N.V. is a focused PatentsView assignee: 9 CPC subclasses with 62.5% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2022 (3 grants) versus a trough of 1 in 2018. By volume, Indigo sits between Incodema3D, LLC and Industries Lassonde Inc..

Indigo's three-year grant acceleration

Indigo Diabetes N.V. shows 7 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Incodema3d

8
Indeed

8
Index Pharmaceuti…

8
Indiggo

8
Indusco

8
Industrial Galvan…

8
Industrial Percep…

8
Industries Lasson…

8
Indigo Diabetes ◀

8

What this shows Indigo holds 8 patents at rank #32,090, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Indigo

By rank, the assignees closest to #32,090 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Indigo's primary technology class.

Indigo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Indigo Diabetes N.V. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	12.5%
2022	3	37.5%
2023	3	37.5%
2024	1	12.5%

Which technologies does Indigo Diabetes N.V. patent most?

A61B - DIAGNOSIS; SURGERY; Identification 5

G02B - Optical Elements, Systems OR Apparatus 5

G01M - Testing Static OR Dynamic Balance OF Machines OR STRUCTURES; Testing OF Structures OR Apparatus, NOT Otherwise Provided FOR 2

B81C - Processes OR Apparatus Specially Adapted FOR THE Manufacture OR Treatment OF Microstructural Devices OR Systems 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 1

G01B - Measuring Length, Thickness OR Similar Linear DIMENSIONS; Measuring ANGLES; Measuring AREAS; Measuring Irregularities OF Surfaces OR Contours 1

B81B - Microstructural Devices OR Systems, e.g. Micromechanical Devices 1

H01L - Semiconductor Devices NOT Covered BY Class H10 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Indigo Diabetes N.V.'s patent record in context - here's where to go next.

Indigo Diabetes N.V.'s lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 62.5% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #32,039 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Indigo Diabetes N.V. against Incodema3D, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.